ArticleJournal of Alzheimer's disease : JAD2010
Differential accumulation of secreted AbetaPP metabolites in ocular fluids.
Article in Journal of Alzheimer's disease : JAD, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 71 citations in OpenAlex.
- Exploring Alzheimer Disease from a Retinal and Ocular Perspective.Biomedicines · 2026Review
- Correlations between amyloid-β peptide levels in aqueous humor and retinal thickness in patients with glaucoma.Scientific reports · 2025Article
- Oculomics: A Crusade Against the Four Horsemen of Chronic Disease.Ophthalmology and therapy · 2024Review
- Bridging Retinal and Cerebral Neurodegeneration: A Focus on Crosslinks between Alzheimer-Perusini's Disease and Retinal Dystrophies.Biomedicines · 2023Review
- The Eye as a Diagnostic Tool for Alzheimer's Disease.Life (Basel, Switzerland) · 2023Review
- Proteomics profiling of vitreous humor reveals complement and coagulation components, adhesion factors, and neurodegeneration markers as discriminatory biomarkers of vitreoretinal eye diseases.Frontiers in immunology · 2023Article
- RAGE and its ligand amyloid beta promote retinal ganglion cell loss following ischemia-reperfusion injury.Frontiers in cellular neuroscience · 2023Article
- An Exploratory Study Provides Insights into MMP9 and Aβ Levels in the Vitreous and Blood across Different Ages and in a Subset of AMD Patients.International journal of molecular sciences · 2022Article
- Alzheimer's Disease Seen through the Eye: Ocular Alterations and Neurodegeneration.International journal of molecular sciences · 2022Review
- Association of cognitive function with Neurofilament light chain in the aqueous humor of human eye.Frontiers in aging neuroscience · 2022Article
- The Lack of Amyloidogenic Activity Is Persistent in Old WT and APPInternational journal of molecular sciences · 2021Article
- Protein and Imaging Biomarkers in the Eye for Early Detection of Alzheimer's Disease.Journal of Alzheimer's disease reports · 2021Review
- Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer's Disease.Acta neuropathologica communications · 2021Article
- Oligomeric AβCells · 2021Article
- Computational Evaluation of Interaction Between Curcumin Derivatives and Amyloid-β Monomers and Fibrils: Relevance to Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2021Article
- The retinal toxicity profile towards assemblies of Amyloid-β indicate the predominant pathophysiological activity of oligomeric species.Scientific reports · 2020Article
- Retinal Degeneration and Alzheimer's Disease: An Evolving Link.International journal of molecular sciences · 2020Review
- Neurofilament light chain in the vitreous humor of the eye.Alzheimer's research & therapy · 2020Article
- Molecular and Imaging Biomarkers in Alzheimer's Disease: A Focus on Recent Insights.Journal of personalized medicine · 2020Review
- Use of ocular biomarkers as a potential tool for early diagnosis of Alzheimer's disease.Indian journal of ophthalmology · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Amyloid-beta (Abeta) accumulates in several types of retinal degeneration and in Alzheimer's disease (AD), but its source has been unclear. We detected the neuronal 695 amino acid form of amyloid-beta protein precursor (AbetaPP) in the normal retina and AbetaPP751 in the retinal pigment epithelium (RPE) and anterior eye tissues. Similar to the brain, alpha- and beta-secretases cleaved AbetaPP to soluble derivatives (sAbetaPP) alpha or beta and membrane-bound C-terminal fragments alpha or beta in the retina and RPE. Levels of sAbetaPP were particularly high in the vitreous and low in aqueous humor revealing a molecular barrier for AbetaPP. In contrast, Abeta40 and Abeta42 levels were only 50% lower in the aqueous than the vitreous humor, indicating relatively barrier-free movement of Abeta. These studies demonstrated a relatively high yield of AbetaPP and Abeta in the ocular fluids, which may serve as a trackable marker for AD. In addition, failure of free clearance from the eye may trigger retina degeneration in a manner similar to Abeta-related neurodegeneration in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.